{"id":476348,"date":"2026-05-09T12:39:26","date_gmt":"2026-05-09T12:39:26","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/476348\/"},"modified":"2026-05-09T12:39:26","modified_gmt":"2026-05-09T12:39:26","slug":"medtronic-stock-outlook-is-wall-street-bullish-or-bearish","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/476348\/","title":{"rendered":"Medtronic Stock Outlook: Is Wall Street Bullish or Bearish?"},"content":{"rendered":"\n<p class=\"yf-1fy9kyt\">With a market cap of\u00a0$99.9 billion, Medtronic plc (MDT) is a global medical technology company that develops, manufactures, and sells device-based therapies to healthcare providers and patients worldwide. The Ireland-based company operates across cardiovascular, neuroscience, medical-surgical, and diabetes care, offering innovative solutions that address a wide range of chronic and acute conditions.<\/p>\n<p class=\"yf-1fy9kyt\">MDT has faced challenges, and its shares have lagged behind the broader market over the past 52 weeks.\u00a0MDT stock has dipped 6.8%\u00a0over this time frame, while the broader S&amp;P 500 Index ($SPX) has\u00a0gained 28.5%. Moreover, the stock has fallen 19% on a YTD basis, trailing the index\u2019s 6% rise.<\/p>\n<p>      More News from Barchart       <\/p>\n<p class=\"yf-1fy9kyt\">Looking closer, shares of the medical device company have also outperformed the State Street Health Care Select Sector SPDR ETF&#8217;s (XLV)\u00a05.2% return\u00a0over the past 52 weeks and 6.1% drop in 2026.<\/p>\n<p>    <img fetchpriority=\"high\" decoding=\"async\" src=\"https:\/\/www.europesays.com\/ie\/wp-content\/uploads\/2026\/05\/b03af3c5bbe3b0d0b8e29310356fe6f2.png\" alt=\"www.barchart.com\" loading=\"eager\" height=\"522\" width=\"786\" class=\"yf-lglytj  loaded\"\/> www.barchart.com      <\/p>\n<p class=\"yf-1fy9kyt\">Medtronic has lagged the broader market over the past year due to slower growth, uncertainty around restructuring, and competitive pressures across key segments. Investors have remained cautious as the company faced softer demand trends in certain medical device categories, foreign exchange headwinds, and margin pressure tied to supply chain and operational costs.<\/p>\n<p class=\"yf-1fy9kyt\">A major overhang has been Medtronic\u2019s diabetes business, which has struggled against stronger competition in the insulin pump and continuous glucose monitoring markets. The company\u2019s decision to separate the diabetes unit has also introduced uncertainty around future earnings growth and portfolio strategy.<\/p>\n<p class=\"yf-1fy9kyt\">For the fiscal year that ended in April 2026, analysts expect MDT\u2019s\u00a0adjusted EPS to grow 1.5% year-over-year\u00a0to $5.57. The company&#8217;s earnings surprise history is promising. It topped the consensus estimates in the last four quarters.<\/p>\n<p class=\"yf-1fy9kyt\">Among the 28 analysts covering the stock, the\u00a0consensus rating\u00a0is a \u201cModerate Buy.\u201d That\u2019s based on 13 \u201cStrong Buy\u201d ratings, two \u201cModerate Buy,\u201d and 13 \u201cHolds.\u201d<\/p>\n<p>    <img decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"www.barchart.com\" loading=\"lazy\" height=\"668\" width=\"783\" class=\"yf-lglytj loader\"\/> www.barchart.com      <\/p>\n<p class=\"yf-1fy9kyt\">This configuration is bearish than two months ago, with 14 \u201cStrong Buy\u201d ratings on the stock.<\/p>\n<p class=\"yf-1fy9kyt\">On Apr. 22, UBS lowered its price target on Medtronic to $90 from $104 while maintaining a \u201cNeutral\u201d rating, as the firm revised its valuation model to account for the company\u2019s planned diabetes business separation.<\/p>\n","protected":false},"excerpt":{"rendered":"With a market cap of\u00a0$99.9 billion, Medtronic plc (MDT) is a global medical technology company that develops, manufactures,&hellip;\n","protected":false},"author":2,"featured_media":476349,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[275],"tags":[5361,18,135,475,474,13106,19,208669,17,32780,13113],"class_list":{"0":"post-476348","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-diabetes-care","9":"tag-eire","10":"tag-health","11":"tag-health-care","12":"tag-healthcare","13":"tag-healthcare-providers","14":"tag-ie","15":"tag-innovative-solutions","16":"tag-ireland","17":"tag-mdt-stock","18":"tag-medtronic"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ie\/116544665380430024","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/476348","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=476348"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/476348\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/476349"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=476348"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=476348"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=476348"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}